蛋白S缺乏症患者的循环中血栓
Clot In Transit in a Patient with Protein S Deficiency.
作者信息
Kashfi Simon, Nasser Mohamed Farhan, Soleiman Aron, Sharma Sapna, Koripalli Venkata Sandeep, Sharma Shorabh
机构信息
CUNY School of Medicine, New York, NY, USA.
Heart and Vascular Center, MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH, USA.
出版信息
Eur J Case Rep Intern Med. 2022 May 5;9(5):003355. doi: 10.12890/2022_003355. eCollection 2022.
UNLABELLED
Clot in transit (CIT) is a rare condition in which a venous thromboembolism becomes lodged in the right heart. It is seen in up to 18% of patients with massive pulmonary embolism, and if left untreated, mortality rates are between 80% and 100%. The identification and management of CIT are crucial. However, there are no current guidelines for the treatment of CIT. We present the case of a 44-year-old woman who was found to have CIT that was ultimately treated with medical management.
LEARNING POINTS
Clot in transit (CIT) is a dangerous entity that must be promptly managed.Risk factors for CIT include a history of heart failure, a pre-existing central venous catheter and recent hospitalization.New interventions are emerging for the treatment of CIT.
未标注
移行性血栓（CIT）是一种罕见的病症，即静脉血栓栓塞栓子滞留于右心。在高达18%的大面积肺栓塞患者中可见，若不治疗，死亡率在80%至100%之间。CIT的识别与处理至关重要。然而，目前尚无治疗CIT的指南。我们报告一例44岁女性患者，其被诊断为CIT，最终接受了药物治疗。
学习要点
移行性血栓（CIT）是一种必须迅速处理的危险病症。CIT的危险因素包括心力衰竭病史、既往存在中心静脉导管以及近期住院。针对CIT的治疗正在出现新的干预措施。
Zotero 插件